CRISPR Therapeutics (CRSP) stock soared 18.22% to an all-time high of $65.13 per share after a $51 million insider trading purchase by director George Simeon. The company reported a 17% increase in net loss to $136 million but a 71.6% rise in revenue to $865 million in the first quarter.

CRISPR Therapeutics AG (CRSP) is gearing up to release its second quarter earnings report in early August 2025. While the stock has shown potential, some believe that other AI stocks offer better returns with less risk. Investors seeking AI opportunities may want to explore other options beyond CRISPR Therapeutics.

Read more at Yahoo Finance: CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading